poisar

Stocks · News reference

Annexon Provides Update on Phase III ARCHER II Trial for Geographic Atrophy

Fiscal.ai

Annexon, Inc. announced it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy during the fourth quarter of 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading